GSK’s (GSK) “Underweight” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their underweight rating on shares of GSK (LON:GSK) in a research report report published on Wednesday, Marketbeat Ratings reports.

Several other brokerages have also issued reports on GSK. Shore Capital reissued a “buy” rating on shares of GSK in a research note on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,850 ($23.35) target price on shares of GSK in a research report on Tuesday, September 3rd. Finally, Berenberg Bank cut their target price on shares of GSK from GBX 1,820 ($22.97) to GBX 1,600 ($20.19) and set a “buy” rating on the stock in a research note on Friday, November 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($22.79).

GSK Stock Performance

Shares of GSK stock opened at GBX 1,329.50 ($16.78) on Wednesday. The company has a market cap of £54.24 billion, a P/E ratio of 1,179.54, a PEG ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The business has a 50-day moving average price of GBX 1,407.02 and a two-hundred day moving average price of GBX 1,527.55. GSK has a 1-year low of GBX 1,282.50 ($16.19) and a 1-year high of GBX 1,823.50 ($23.02).

GSK Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th will be issued a dividend of GBX 15 ($0.19) per share. This represents a dividend yield of 1.03%. The ex-dividend date is Thursday, November 14th. GSK’s dividend payout ratio is currently 5,309.73%.

Insider Transactions at GSK

In related news, insider Jonathan Symonds bought 7,150 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of GBX 1,394 ($17.59) per share, with a total value of £99,671 ($125,799.57). Also, insider Elizabeth (Liz) McKee Anderson purchased 446 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average price of GBX 2,051 ($25.89) per share, with a total value of £9,147.46 ($11,545.45). Insiders acquired a total of 7,604 shares of company stock valued at $10,893,038 over the last three months. Corporate insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.